Table 2.
Patient characteristics for study population, commercial/Medicare supplemental adults at high risk for severe RSV.
| Patient Characteristics | 2017–2018 N = 2,493,686 |
2018–2019 N = 2,649,397 |
|---|---|---|
| Age (years)a | ||
| Mean (SD) | 57.00 (15.05) | 54.88 (14.67) |
| Median [IQR] | 58.00 [48.00, 64.00] | 56.00 [47.00, 63.00] |
| Sex, n (%)a | ||
| Female | 1,291,014 (51.8%) | 1,372,301 (51.8%) |
| Male | 1,202,672 (48.2%) | 1,277,096 (48.2%) |
| US geographic region, n (%)a,b | ||
| Northeast | 490,658 (19.7%) | 566,705 (21.4%) |
| North Central | 550,516 (22.1%) | 589,717 (22.3%) |
| South | 1,149,262 (46.1%) | 1,167,223 (44.1%) |
| West | 299,338 (12.0%) | 320,622 (12.1%) |
| Unknown | 3912 (0.2%) | 5130 (0.2%) |
| Payer type, n (%)c | ||
| Commercial | 1,897,421 (76.1%) | 2,200,488 (83.1%) |
| Medicare Supplemental | 596,265 (23.9%) | 448,909 (16.9%) |
| Conditions at high risk of severe RSV, n (%)c | ||
| Chronic obstructive pulmonary disease | 163,210 (6.5%) | 152,964 (5.8%) |
| Asthma | 340,201 (13.6%) | 502,778 (19.0%) |
| Diabetes mellitus | 1,233,399 (49.5%) | 1,227,110 (46.3%) |
| Congestive heart failure | 130,899 (5.2%) | 127,058 (4.8%) |
| Advanced liver disease | 190,091 (7.6%) | 261,610 (9.9%) |
| Chronic kidney disease or end-stage renal disease | 230,554 (9.2%) | 234,860 (8.9%) |
| Coronary artery disease | 387,386 (15.5%) | 401,744 (15.2%) |
| Immunocompromised status, n (%)d | 561,180 (22.5%) | 539,296 (20.4%) |
| Combined comorbidity indexc,e | ||
| Mean (SD) | 1.32 (2.11) | 1.37 (2.07) |
| Median [IQR] | 1.00 [0.00, 2.00] | 1.00 [0.00, 2.00] |
| Claims-based frailty index, n (%)c,f | ||
| Robust (<0.25) | 1,704,850 (68.4%) | 1,861,011 (70.2%) |
| Prefrail or mild frailty (0.25 to <0.35) | 779,170 (31.2%) | 779,343 (29.4%) |
| Moderate to severe frailty (≥0.35) | 9666 (0.4%) | 9043 (0.3%) |
| Length of follow-up (days), mean (SD)g | 269.71 (121.02) | 257.18 (117.07) |
Abbreviations: ICD = International Classification of Diseases; IQR = interquartile range; RSV = respiratory syncytial virus; SD = standard deviation; US = United States.
aAssessed on cohort entry date.
bUS geographic region data is only available in MarketScan’s Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases and is not available in the Multi-State Medicaid database.
cAssessed in the 242 d and 365 d before cohort entry in 2017–2018 and 2018–2019, respectively, corresponding to the baseline period for each study year.
dAssessed using varying lookback periods before cohort entry, based on Polinski et al.27
gLength of follow-up is presented in days. Patients were followed from cohort entry until their first ICD-coded cardiorespiratory hospitalization, disenrollment, or the end of study year.